ARCHIVES

J&J To Eliminate Its Ortho Biotech Unit As FDA Considers Further Limits On ESAs.

This article is from The Cancer Letter archive.

Vol. 34 No. 17 | May 2, 2008

Download PDF Visit The Full Archive

Related Articles

Centers May Become More specialized, Klausner Tells AACI

April 26, 1996

Salick Raises Nearly $50 Million, Proceeding With FCC Development

June 6, 1986

NCI Contracts: Advisors OK Renewal Of chemoprevention Contracts By DCPC

September 6, 1996

Satcher Nominated For Surgeon General, Asst. Sec. for Health.

September 19, 1997

ImClone Protocol Generates More Questions Than Answers

March 8, 2002

In Brief: House Passes FY ’77 Money Bill, But Veto Seems Likely; NIH Relaxes Moonlighting Rule

August 20, 1976